Annexon
ANNX
Market cap $764M

7.23 USD

-0.13

1.77%

At close Nov 8, 4:00 PM EST

After hours

6.88

-0.35

4.84%

1 day

-1.77%

5 days

0.14%

1 month

4.93%

3 months

31.69%

6 months

48.46%

Year to date

49.38%

1 year

233.18%

5 years

-59.29%

About: Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Employees: 71

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,759 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

150% more call options, than puts

Call options by funds: $26.3M | Put options by funds: $10.5M

121% more capital invested

Capital invested by funds: $692M [Q1] → $1.53B (+$835M) [Q2]

56% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 25

56% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 34

11% more funds holding

Funds holding: 126 [Q1] → 140 (+14) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

17.38% less ownership

Funds ownership: 123.58% [Q1] → 106.2% (-17.38%) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$16

121%

upside

Avg. target

$23

218%

upside

High target

$30

315%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Andrew Fein 51% 1-year accuracy 98 / 193 met price target	315%upside $30	Buy Reiterated	13 Aug 2024
Needham Joseph Stringer 69% 1-year accuracy 90 / 130 met price target	121%upside $16	Buy Reiterated	13 Aug 2024

See Analyst Rankings

Financial journalist opinion

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Enhanced protection of vision with ANX007 treatment in healthier eyes Greater preservation of EZ in the central fovea by ANX007 in patients with less advanced GA Pivotal Phase 3 ARCHER II Data Expected Second Half 2026 BRISBANE, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced new findings from its Phase 2 ARCHER study for ANX007 in geographic atrophy (GA) due to dry age-related macular degeneration (AMD).

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

On October 1, 2024, Director William Carson purchased 3,200 shares of Annexon Inc (ANNX, Financial), as reported in a recent SEC Filing. The transaction occurred at a price of $5.97 per share, totaling $19,104.

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Annexon's ANX005 shows promise for GBS. Phase 3 trial results indicate expedited recovery and durable benefits. ANNX targets the classical complement pathway, specifically the C1q protein, to address autoimmune, neurodegenerative, and ophthalmic conditions. The company's pipeline includes ANX005, ANX007, and ANX1502. Due to its advanced development stage, ANX005 is the primary value driver.

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and eye, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on August 15, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel therapies for neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on July 11, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Zacks Investment Research

Are Medical Stocks Lagging Annexon (ANNX) This Year?

Here is how Annexon, Inc. (ANNX) and CareCloud, Inc. (CCLD) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Annexon (ANNX) This Year?

Zacks Investment Research

Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now

After losing some value lately, a hammer chart pattern has been formed for Annexon (ANNX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on June 14, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

See News Rankings

Charts implemented using Lightweight Charts™